Roche Obesity Trial Success Sparks Fresh Look At Valuation And Pipeline [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Roche Holding (SWX:ROG) reported positive Phase II results from its ZUPREME-1 trial of petrelintide in obesity. The study showed meaningful weight loss and strong tolerability in participants. The data are seen as an important step for Roche's broader obesity pipeline and potential future combination therapies. For investors watching SWX:ROG, this update comes with the stock at around CHF341.2 and a 1 year return of 14.8%. The shares have seen a 44.4% return over 3 years and 32.2% over 5 years, which gives some context for how the market has treated Roche over different time frames. The ZUPREME-1 readout feeds directly into Roche's push in metabolic disease, alongside its recent partnerships and pipeline build out. As more details emerge on regulatory plans and possible combination approaches, investors may focus on how petrelintide could fit into the broader o
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designationPR Newswire
- R1 Therapeutics raises $77.5m to progress AP306 for hyperphosphatemia [Yahoo! Finance]Yahoo! Finance
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
- Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions [Yahoo! Finance]Yahoo! Finance
- Making space for everyday life with spinal muscular atrophy [USA TODAY]USA TODAY